


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.31%
-1.07%
-0.08%
PCVX
Vaxcyte
$53.40
Strengths

Upgraded on attractively valued

Trading below its fair value

Earnings are forecast to grow
PCVX Price Performance
$46.97 (+13.69%)
$43.52 (+22.70%)
$31.56 (+69.20%)
$85.94 (-37.86%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Trading below its fair value

Earnings are forecast to grow
![]()
PCVX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PCVX Street Sentiment is extremely bullish and have positive views on the near-term outlook
PCVX has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
PCVX
Vaxcyte
53.40
+1.27%
LEGN
Legend Biotech Corporatio
18.96
-0.26%
TEVA
Teva Pharma
32.14
+1.04%
QS
QuantumScape
9.91
-4.34%
MTZ
MasTec
245.29
+1.44%
What is PCVX current stock price?
What are PCVX stock strengths?
What is PCVX Risk Level?
What is PCVX market cap and volume?
What is PCVX current Stock IQ?
Should I buy PCVX stock right now?
Is PCVX a Strong Buy right now?
What does a 'Strong Buy' rating mean for PCVX?
What does a 'Strong Sell' rating mean for PCVX?
What factors influence PCVX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.31%
-1.07%
-0.08%
PCVX
Vaxcyte
Current Price
$53.40
Stock Insights
Strengths

Upgraded on attractively valued

Trading below its fair value

Earnings are forecast to grow
Recently Viewed
PCVX
Vaxcyte
53.40
+1.27%
LEGN
Legend Biotech Corporatio
18.96
-0.26%
TEVA
Teva Pharma
32.14
+1.04%
QS
QuantumScape
9.91
-4.34%
MTZ
MasTec
245.29
+1.44%

PCVX Price Performance
$46.97 (+13.69%)
$43.52 (+22.70%)
$31.56 (+69.20%)
$85.94 (-37.86%)
PCVX Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Trading below its fair value

Earnings are forecast to grow
![]()
PCVX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PCVX Street Sentiment is extremely bullish and have positive views on the near-term outlook
PCVX has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Nov 11, 2025
Reiterate
her Buy
TD Cowen
Nov 10, 2025
Reiterate
Buy
BTIG
PCVX Stock IQ
PCVX Latest Analysis
Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations. Vaxcyte Inc. (NASDAQ:PCVX) is one of the best US stocks to buy under $50. On January 23 Cantor Fitzgerald reaffirmed its Overweight rating on Vaxcyte Inc. (NASDAQ:PCVX) keeping a positive view as the company advances its vaccine pipeline on schedule. The firm expects topline results from the Phase 3 OPUS-1 trial in late 2026 with [….]
Mon Jan 26, 2026
Vaxcyte Advances Clinical Development Of Next-Gen Pneumococcal Vaccine. On Track For BLA Submission . (RTTNews) - Vaxcyte Inc. (PCVX) is advancing both its adult and infant programs for VAX-31 a 31-valent pneumococcal conjugate vaccine candidate that represents the broadest-spectrum in clinical development today as the company moves toward a planned Biologics License Applicati
Fri Jan 23, 2026
Vaxcyte Advances Adult and Infant Programs for VAX-31 a Potential Best-in-Class Next-Generation Pneumococcal Conjugate Vaccine. VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults Previously Vaccinated with Pneumococcal Vaccines (OPUS-3) in First Quarter of 2026
Thu Jan 22, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
PCVX Stock trends
PCVX Stock performance
PCVX Stock analysis
PCVX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.